Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Johnson and Johnson
UBS
Cerilliant
Cipla
McKesson
Novartis
Medtronic
Moodys
Dow

Generated: January 22, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,964,580

« Back to Dashboard

Summary for Patent: 7,964,580
Title:Nucleoside phosphoramidate prodrugs
Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: ##STR00001## Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Inventor(s): Sofia; Michael Joseph (Doylestown, PA), Du; Jinfa (New Hope, PA), Wang; Peiyuan (Glen Rock, NJ)
Assignee: Pharmasset, Inc. (Princeton, NJ)
Application Number:12/053,015
Patent Claims: 1. (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fl- uoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylam- ino}-propionic acid isopropyl ester or a stereoisomer thereof.

2. A composition comprising the compound or a stereoisomer thereof as claimed in claim 1 and a pharmaceutically acceptable medium.

3. A composition for treating a hepatitis C virus, which comprises an effective amount of the compound or a stereoisomer thereof as claimed in claim 1 and a pharmaceutically acceptable medium.

4. A method of treating a subject infected by a virus, which comprises: administering to the subject an effective amount of the compound or a stereoisomer thereof as claimed in claim 1; wherein the virus is selected from among hepatitis C virus, West Nile virus, a yellow fever virus, a dengue virus, a rhinovirus, a polio virus, a hepatitis A virus, a bovine viral diarrhea virus, and a Japanese encephalitis virus.

5. A method of treating a hepatitis C virus infection in a subject in need thereof, which comprises: administering to the subject an effective amount of the compound or a stereoisomer thereof as claimed in claim 1.

6. A process for preparing the compound or a stereoisomer thereof as claimed in claim 1, said process comprising: reacting a compound 4'' with a nucleoside analog 5' ##STR00092## wherein X' is a leaving group.

7. A product comprising the compound or a stereoisomer thereof as claimed in claim 1 obtained by a process comprising: reacting a compound 4'' with a nucleoside analog 5' ##STR00093## wherein X' is a leaving group.

8. (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-flu- oro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)ami- no)propanoate.

9. A composition comprising the compound as claimed in claim 8 and a pharmaceutically acceptable medium.

10. A composition for treating a hepatitis C virus, which comprises an effective amount of the compound as claimed in claim 8 and a pharmaceutically acceptable medium.

11. A method of treating a subject infected by a virus, which comprises: administering to the subject an effective amount of the compound as claimed in claim 8; wherein the virus is selected from among hepatitis C virus, West Nile virus, a yellow fever virus, a dengue virus, a rhinovirus, a polio virus, a hepatitis A virus, a bovine viral diarrhea virus, and a Japanese encephalitis virus.

12. A method of treating a hepatitis C virus infection in a subject in need thereof, which comprises: administering to the subject an effective amount of the compound as claimed in claim 8.

13. A process for preparing the compound as claimed in claim 8, said process comprising: reacting a compound 4'' with a nucleoside analog 5' ##STR00094## wherein X' is a leaving group.

14. A product comprising the compound as claimed in claim 8 obtained by a process comprising: reacting a compound 4'' with a nucleoside analog 5' ##STR00095## wherein X' is a leaving group.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Teva
UBS
Daiichi Sankyo
Fish and Richardson
US Army
Deloitte
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot